Gag-specific immune enhancement of lentiviral infection after vaccination with an adenoviral vector in an animal model of AIDS

Vaccine

Volumn 27, Issue 6, 2009, Pages 928-939

  Klonjkowski, Bernard ^a   Klein, Dieter ^b   Galea, Sandra ^a   Gavard, Françoise ^a   Monteil, Martine ^a   Duarte, Lidia ^a   Fournier, Annie ^a   Sayon, Sophie ^a   Górna, Kamila ^a   Ertl, Reinhard ^b   Cordonnier, Nathalie ^a   Sonigo, Pierre ^c   Eloit, Marc ^a   Richardson, Jennifer ^a  

^a ECOLE NATIONALE VÉTÉRINAIRE D ALFORT   (France)

^b UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^c Bio Rad   (France)

Author keywords

Adenoviral vector; Canine adenovirus; Enhancement; Feline immunodeficiency virus

Indexed keywords

ADENOVIRUS VECTOR; GAG PROTEIN; GREEN FLUORESCENT PROTEIN; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CAT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE EXACERBATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL MODEL; FELINE IMMUNODEFICIENCY VIRUS; FEMALE; HUMORAL IMMUNITY; IMMUNITY; IMMUNIZATION; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIMATE; PRIORITY JOURNAL; RETROVIRUS INFECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA VIRUS; TRANSGENE; VACCINATION;

ADENOVIRIDAE; AIDS VACCINES; ANIMALS; ANTIBODIES, VIRAL; CATS; CD4-CD8 RATIO; ENZYME-LINKED IMMUNOSORBENT ASSAY; FELINE ACQUIRED IMMUNODEFICIENCY SYNDROME; FEMALE; GENE PRODUCTS, ENV; GENE PRODUCTS, GAG; IMMUNIZATION, SECONDARY; IMMUNODEFICIENCY VIRUS, FELINE; MALE; MICE; MICE, INBRED BALB C; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; VIRAL LOAD;

EID: 58249137743     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.11.086     Document Type: Article

References (91)

1. Apetrei C., Kaur A., Lerche N.W., Metzger M., Pandrea I., Hardcastle J., et al. Molecular epidemiology of simian immunodeficiency virus SIVsm in U.S. primate centers unravels the origin of SIVmac and SIVstm. J Virol 79 14 (2005) 8991-9005
2. Gardner M.B. The history of simian AIDS. J Med Primatol 25 3 (1996) 148-157
3. Dalgleish A.G., Beverley P.C., Clapham P.R., Crawford D.H., Greaves M.F., and Weiss R.A. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312 5996 (1984) 763-767
4. Shimojima M., Miyazawa T., Ikeda Y., McMonagle E.L., Haining H., Akashi H., et al. Use of CD134 as a primary receptor by the feline immunodeficiency virus. Science 303 5661 (2004) 1192-1195
5. Brown W.C., Bissey L., Logan K.S., Pedersen N.C., Elder J.H., and Collisson E.W. Feline immunodeficiency virus infects both CD4+ and CD8+ T lymphocytes. J Virol 65 6 (1991) 3359-3364
6. English R.V., Johnson C.M., Gebhard D.H., and Tompkins M.B. In vivo lymphocyte tropism of feline immunodeficiency virus. J Virol 67 9 (1993) 5175-5186
7. Burton D.R. Antibodies, viruses and vaccines. Nat Rev Immunol 2 9 (2002) 706-713
8. Karlsson Hedestam G.B., Fouchier R.A., Phogat S., Burton D.R., Sodroski J., and Wyatt R.T. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 6 2 (2008) 143-155
9. Bernard N.F., Pederson K., Chung F., Ouellet L., Wainberg M.A., and Tsoukas C.M. HIV-specific cytotoxic T-lymphocyte activity in immunologically normal HIV-infected persons. AIDS 12 16 (1998) 2125-2139
10. Borrow P., Lewicki H., Hahn B.H., Shaw G.M., and Oldstone M.B. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 68 9 (1994) 6103-6110
11. Koup R.A., Safrit J.T., Cao Y., Andrews C.A., McLeod G., Borkowsky W., et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 68 7 (1994) 4650-4655
12. Migueles S.A., Laborico A.C., Shupert W.L., Sabbaghian M.S., Rabin R., Hallahan C.W., et al. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 3 11 (2002) 1061-1068
13. Pontesilli O., Klein M.R., Kerkhof-Garde S.R., Pakker N.G., de Wolf F., Schuitemaker H., et al. Longitudinal analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte responses: a predominant gag-specific response is associated with nonprogressive infection. J Infect Dis 178 4 (1998) 1008-1018
14. Schmitz J.E., Kuroda M.J., Santra S., Sasseville V.G., Simon M.A., Lifton M.A., et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283 5403 (1999) 857-860
15. Barouch D.H., and Nabel G.J. Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum Gene Ther 16 2 (2005) 149-156
16. Santosuosso M., McCormick S., and Xing Z. Adenoviral vectors for mucosal vaccination against infectious diseases. Viral Immunol 18 2 (2005) 283-291
17. Tatsis N., and Ertl H.C. Adenoviruses as vaccine vectors. Mol Ther 10 4 (2004) 616-629
18. Machado A.V., Cardoso J.E., Claser C., Rodrigues M.M., Gazzinelli R.T., and Bruna-Romero O. Long-term protective immunity induced against Trypanosoma cruzi infection after vaccination with recombinant adenoviruses encoding amastigote surface protein-2 and trans-sialidase. Hum Gene Ther 17 9 (2006) 898-908
19. Sullivan N.J., Geisbert T.W., Geisbert J.B., Shedlock D.J., Xu L., Lamoreaux L., et al. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med 3 6 (2006) e177
20. Yu J.R., Kim S., Lee J.B., and Chang J. Single intranasal immunization with recombinant adenovirus-based vaccine induces protective immunity against respiratory syncytial virus infection. J Virol 82 5 (2008) 2350-2357
21. Casimiro D.R., Chen L., Fu T.M., Evans R.K., Caulfield M.J., Davies M.E., et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 77 11 (2003) 6305-6313
22. Millar J., Dissanayake D., Yang T.C., Grinshtein N., Evelegh C., Wan Y., et al. The magnitude of the CD8+ T cell response produced by recombinant virus vectors is a function of both the antigen and the vector. Cell Immunol 250 1-2 (2007) 55-67
23. Shiver J.W., Fu T.M., Chen L., Casimiro D.R., Davies M.E., Evans R.K., et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415 6869 (2002) 331-335
24. Hartman Z.C., Appledorn D.M., and Amalfitano A. Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res 132 1-2 (2008) 1-14
25. Muruve D.A. The innate immune response to adenovirus vectors. Hum Gene Ther 15 12 (2004) 1157-1166
26. Nwanegbo E., Vardas E., Gao W., Whittle H., Sun H., Rowe D., et al. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol 11 2 (2004) 351-357
27. Vogels R., Zuijdgeest D., van Rijnsoever R., Hartkoorn E., Damen I., de Bethune M.P., et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 77 15 (2003) 8263-8271
28. Barouch D.H., McKay P.F., Sumida S.M., Santra S., Jackson S.S., Gorgone D.A., et al. Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines. J Virol 77 16 (2003) 8729-8735
29. Barouch D.H., Pau M.G., Custers J.H., Koudstaal W., Kostense S., Havenga M.J., et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 172 10 (2004) 6290-6297
30. Fitzgerald J.C., Gao G.P., Reyes-Sandoval A., Pavlakis G.N., Xiang Z.Q., Wlazlo A.P., et al. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol 170 3 (2003) 1416-1422
31. Yang Z.Y., Wyatt L.S., Kong W.P., Moodie Z., Moss B., and Nabel G.J. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol 77 1 (2003) 799-803
32. Bangari D.S., and Mittal S.K. Current strategies and future directions for eluding adenoviral vector immunity. Curr Gene Ther 6 2 (2006) 215-226
33. Bangari D.S., and Mittal S.K. Development of nonhuman adenoviruses as vaccine vectors. Vaccine 24 7 (2006) 849-862
34. Perreau M., and Kremer E.J. The conundrum between immunological memory to adenovirus and their use as vectors in clinical gene therapy. Mol Biotechnol 34 2 (2006) 247-256
35. Graham F.L., Smiley J., Russell W.C., and Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36 1 (1977) 59-74
36. Moraillon A., Barre-Sinoussi F., Parodi A., Moraillon R., and Dauguet C. In vitro properties and experimental pathogenic effect of three strains of feline immunodeficiency viruses (FIV) isolated from cats with terminal disease. Vet Microbiol 31 1 (1992) 41-54
37. Richardson J., Pancino G., Merat R., Leste-Lasserre T., Moraillon A., Schneider-Mergener J., et al. Shared usage of the chemokine receptor CXCR4 by primary and laboratory-adapted strains of feline immunodeficiency virus. J Virol 73 5 (1999) 3661-3671
38. Chartier C., Degryse E., Gantzer M., Dieterle A., Pavirani A., and Mehtali M. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol 70 7 (1996) 4805-4810
39. Pancino G., Chappey C., Saurin W., and Sonigo P. B epitopes and selection pressures in feline immunodeficiency virus envelope glycoproteins. J Virol 67 2 (1993) 664-672
40. Reid G., Rigby M.A., McDonald M., Hosie M.J., Neil J.C., and Jarrett O. Immunodiagnosis of feline immunodeficiency virus infection using recombinant viral p17 and p24. AIDS 5 12 (1991) 1477-1483
41. Klein D., Leutenegger C.M., Bahula C., Gold P., Hofmann-Lehmann R., Salmons B., et al. Influence of preassay and sequence variations on viral load determination by a multiplex real-time reverse transcriptase-polymerase chain reaction for feline immunodeficiency virus. J Acquir Immune Defic Syndr 26 1 (2001) 8-20
42. Klein D., Bugl B., Gunzburg W.H., and Salmons B. Accurate estimation of transduction efficiency necessitates a multiplex real-time PCR. Gene Ther 7 6 (2000) 458-463
43. Hu R., Zhang S., Fooks A.R., Yuan H., Liu Y., Li H., et al. Prevention of rabies virus infection in dogs by a recombinant canine adenovirus type-2 encoding the rabies virus glycoprotein. Microbes Infect 8 4 (2006) 1090-1097
44. Li J., Faber M., Papaneri A., Faber M.L., McGettigan J.P., Schnell M.J., et al. A single immunization with a recombinant canine adenovirus expressing the rabies virus G protein confers protective immunity against rabies in mice. Virology 356 1-2 (2006) 147-154
45. Liu Y., Hu R., Zhang S., Zhang F., Li Z., Wei X., et al. Expression of the Foot-and-Mouth Disease Virus VP1 protein using a replication-competent recombinant canine adenovirus type 2 elicits a humoral antibody response in a porcine model. Viral Immunol 19 2 (2006) 202-209
46. Hu R.L., Liu Y., Zhang S.F., Zhang F., and Fooks A.R. Experimental immunization of cats with a recombinant rabies-canine adenovirus vaccine elicits a long-lasting neutralizing antibody response against rabies. Vaccine 25 29 (2007) 5301-5307
47. Yang S., Xia X., Qiao J., Liu Q., Chang S., Xie Z., et al. Complete protection of cats against feline panleukopenia virus challenge by a recombinant canine adenovirus type 2 expressing VP2 from FPV. Vaccine 26 11 (2008) 1482-1487
48. Delchambre M., Gheysen D., Thines D., Thiriart C., Jacobs E., Verdin E., et al. The GAG precursor of simian immunodeficiency virus assembles into virus-like particles. EMBO J 8 9 (1989) 2653-2660
49. Karacostas V., Nagashima K., Gonda M.A., and Moss B. Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector. Proc Natl Acad Sci U S A 86 22 (1989) 8964-8967
50. Deml L., Speth C., Dierich M.P., Wolf H., and Wagner R. Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses. Mol Immunol 42 2 (2005) 259-277
51. Takada A., and Kawaoka Y. Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev Med Virol 13 6 (2003) 387-398
52. Thomas S., Redfern J.B., Lidbury B.A., and Mahalingam S. Antibody-dependent enhancement and vaccine development. Expert Rev Vaccines 5 4 (2006) 409-412
53. Ascher M.S., and Sheppard H.W. AIDS as immune system activation: II. The panergic imnesia hypothesis. J Acquir Immune Defic Syndr 3 2 (1990) 177-191
54. Bukrinsky M.I., Stanwick T.L., Dempsey M.P., and Stevenson M. Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science 254 5030 (1991) 423-427
55. Zack J.A., Arrigo S.J., Weitsman S.R., Go A.S., Haislip A., and Chen I.S. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 61 2 (1990) 213-222
56. Bentwich Z., Maartens G., Torten D., Lal A.A., and Lal R.B. Concurrent infections and HIV pathogenesis. AIDS 14 14 (2000) 2071-2081
57. Bush C.E., Donovan R.M., Markowitz N.P., Kvale P., and Saravolatz L.D. A study of HIV RNA viral load in AIDS patients with bacterial pneumonia. J Acquir Immune Defic Syndr Hum Retrovirol 13 1 (1996) 23-26
58. Goletti D., Weissman D., Jackson R.W., Graham N.M., Vlahov D., Klein R.S., et al. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol 157 3 (1996) 1271-1278
59. Brichacek B., Swindells S., Janoff E.N., Pirruccello S., and Stevenson M. Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine. J Infect Dis 174 6 (1996) 1191-1199
60. O'Brien W.A., Grovit-Ferbas K., Namazi A., Ovcak-Derzic S., Wang H.J., Park J., et al. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood 86 3 (1995) 1082-1089
61. Ortigao-de-Sampaio M.B., Shattock R.J., Hayes P., Griffin G.E., Linhares-de-Carvalho M.I., Ponce d., et al. Increase in plasma viral load after oral cholera immunization of HIV-infected subjects. AIDS 12 14 (1998) F145-F150
62. Ostrowski M.A., Krakauer D.C., Li Y., Justement S.J., Learn G., Ehler L.A., et al. Effect of immune activation on the dynamics of human immunodeficiency virus replication and on the distribution of viral quasispecies. J Virol 72 10 (1998) 7772-7784
63. Stanley S.K., Ostrowski M.A., Justement J.S., Gantt K., Hedayati S., Mannix M., et al. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 334 19 (1996) 1222-1230
64. Staprans S.I., Hamilton B.L., Follansbee S.E., Elbeik T., Barbosa P., Grant R.M., et al. Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med 182 6 (1995) 1727-1737
65. Davey Jr. R.T., Chaitt D.G., Piscitelli S.C., Wells M., Kovacs J.A., Walker R.E., et al. Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons. J Infect Dis 175 4 (1997) 781-789
66. Kovacs J.A., Baseler M., Dewar R.J., Vogel S., Davey Jr. R.T., Falloon J., et al. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N Engl J Med 332 9 (1995) 567-575
67. Richardson J., Moraillon A., Baud S., Cuisinier A.M., Sonigo P., and Pancino G. Enhancement of feline immunodeficiency virus (FIV) infection after DNA vaccination with the FIV envelope. J Virol 71 12 (1997) 9640-9649
68. Richardson J., Broche S., Baud S., Leste-Lasserre T., Femenia F., Levy D., et al. Lymphoid activation: a confounding factor in AIDS vaccine development?. J Gen Virol 83 Pt 10 (2002) 2515-2521
69. Hosie M.J., Osborne R., Reid G., Neil J.C., and Jarrett O. Enhancement after feline immunodeficiency virus vaccination. Vet Immunol Immunopathol 35 1-2 (1992) 191-197
70. Huisman W., Karlas J.A., Siebelink K.H., Huisman R.C., de Ronde A., Francis M.J., et al. Feline immunodeficiency virus subunit vaccines that induce virus neutralising antibodies but no protection against challenge infection. Vaccine 16 2-3 (1998) 181-187
71. Pistello M., Bonci F., Flynn J.N., Mazzetti P., Isola P., Zabogli E., et al. AIDS vaccination studies with an ex vivo feline immunodeficiency virus model: analysis of the accessory ORF-A protein and DNA as protective immunogens. J Virol 80 18 (2006) 8856-8868
72. Siebelink K.H., Tijhaar E., Huisman R.C., Huisman W., de Ronde A., Darby I.H., et al. Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines. J Virol 69 6 (1995) 3704-3711
73. Dunham S.P., Bruce J., Klein D., Flynn J.N., Golder M.C., MacDonald S., et al. Prime-boost vaccination using DNA and whole inactivated virus vaccines provides limited protection against virulent feline immunodeficiency virus. Vaccine 24 49-50 (2006) 7095-7108
74. Giannecchini S., Isola P., Sichi O., Matteucci D., Pistello M., Zaccaro L., et al. AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: failure to protect and possible enhancement of challenge infection by four cell-based vaccines prepared with autologous lymphoblasts. J Virol 76 14 (2002) 6882-6892
75. Karlas J.A., Siebelink K.H., Peer M.A., Huisman W., Rimmelzwaan G.F., and Osterhaus A.D. Accelerated viraemia in cats vaccinated with fixed autologous FIV-infected cells. Vet Immunol Immunopathol 65 2-4 (1998) 353-365
76. Karlas J.A., Siebelink K.H., Peer M.A., Huisman W., Cuisinier A.M., Rimmelzwaan G.F., et al. Vaccination with experimental feline immunodeficiency virus vaccines, based on autologous infected cells, elicits enhancement of homologous challenge infection. J Gen Virol 80 Pt. 3 (1999) 761-765
77. Nenci C., Zahno M.L., Vogt H.R., Obexer-Ruff G., Doherr M.G., Zanoni R., et al. Vaccination with a T-cell-priming Gag peptide of caprine arthritis encephalitis virus enhances virus replication transiently in vivo. J Gen Virol 88 Pt 5 (2007) 1589-1593
78. Torsteinsdottir S., Carlsdottir H.M., Svansson V., Matthiasdottir S., Martin A.H., and Petursson G. Vaccination of sheep with Maedi-visna virus gag gene and protein, beneficial or harmful?. Vaccine 25 37-38 (2007) 6713-6720
79. Staprans S.I., Barry A.P., Silvestri G., Safrit J.T., Kozyr N., Sumpter B., et al. Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein. Proc Natl Acad Sci. U S A 101 35 (2004) 13026-13031
80. Steger K.K., Waterman P.M., and Pauza C.D. Acute effects of pathogenic simian-human immunodeficiency virus challenge on vaccine-induced cellular and humoral immune responses to Gag in rhesus macaques. J Virol 73 3 (1999) 1853-1859
81. Douek D.C., Brenchley J.M., Betts M.R., Ambrozak D.R., Hill B.J., Okamoto Y., et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 417 6884 (2002) 95-98
82. Schwartz D.H. Potential pitfalls on the road to an effective HIV vaccine. Immunol Today 15 2 (1994) 54-57
83. Anonymous. HIV vaccine failure prompts Merck to halt trial. Nature 449 (2007) 390
84. Cohen J. AIDS research. Promising AIDS vaccine's failure leaves field reeling. Science 318 5847 (2007) 28-29
85. Ledford H. HIV vaccine may raise risk. Nature 450 7168 (2007) 325
86. Sumida S.M., Truitt D.M., Kishko M.G., Arthur J.C., Jackson S.S., Gorgone D.A., et al. Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J Virol 78 6 (2004) 2666-2673
87. Molinier-Frenkel V., Gahery-Segard H., Mehtali M., Le Boulaire C., Ribault S., Boulanger P., et al. Immune response to recombinant adenovirus in humans: capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes. J Virol 74 16 (2000) 7678-7682
88. Toogood C.I., Crompton J., and Hay R.T. Antipeptide antisera define neutralizing epitopes on the adenovirus hexon. J Gen Virol 73 Pt 6 (1992) 1429-1435
89. Sumida S.M., Truitt D.M., Lemckert A.A., Vogels R., Custers J.H., Addo M.M., et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol 174 11 (2005) 7179-7185
90. Pantaleo G. HIV-1 T-cell vaccines: evaluating the next step. Lancet Infect Dis 8 2 (2008) 82-83
91. Haase A.T. Perils at mucosal front lines for HIV and SIV and their hosts. Nat Rev Immunol 5 10 (2005) 783-792